Install
Research & Evidence
Trial design, systematic reviews, medical statistics, and guideline updates.
- 4 Tracked terms
- Last 30 days Feed window
What this topic collects on
An article joins this feed when it matches these terms. Each one is also a search of its own.
Related topics
Latest in Research & Evidence
Novo: CagriSema Shows Greater Weight Loss Than Tirzepatide In Trial
11+ hour, 30+ min ago (21+ words) TradingView Novo: CagriSema Shows Greater Weight Loss Than Tirzepatide In Trial...
J&J’s Caplyta posts rapid Phase III benefit in bipolar mania
6+ hour, 31+ min ago (551+ words) AllSci Johnson & Johnson's (NYSE: JNJ) lumateperone (Caplyta) produced a statistically significant reduction in manic symptoms in bipolar I disorder in a pivotal Phase III trial, according to topline results released September 21 and presented at the 2026 Psych Congress Annual Meeting. Already…...
J&J sees positive late-stage data for Caplyta in reducing bipolar manic symptoms
6+ hour, 18+ min ago (23+ words) Johnson & Johnson reports phase 3 Caplyta data showing rapid reduction in bipolar I mania symptoms vs. placebo by week 3. Read more here....
Author whose son beat rare cancer says sharing the story publicly helped other families
7+ hour, 1+ min ago (30+ words) CBS News Author whose son beat rare cancer says sharing the story publicly helped other families...
Addressing the global trial enrolment challenge
13+ hour, 26+ min ago (192+ words) The 2026 Outsourcing in Clinical Trials New England conference headlines recruitment among major challenges to clinical trials. This October will see experts meet in the biotech hub of Boston to assess the scale and solutions for the leading challenges facing clinical…...
CagriSema bests tirzepatide for weight loss in type 2 diabetes
8+ hour, 4+ min ago (59+ words) CagriSema conferred a greater weight reduction than tirzepatide for adults with type 2 diabetes, and induced weight loss of 21% at 68 weeks for those with overweight or obesity without diabetes, according to topline results from two trials. Novo Nordisk announced data from…...
CagriSema Tops Eli Lilly's Tirzepatide for Weight Loss in Late-Stage Diabetes Trial: Report
3+ hour, 47+ min ago (303+ words) Novo Nordisk reports that CagriSema delivered 12.4% average weight loss in a late-stage diabetes trial, outperforming tirzepatide's 9.1% at comparable doses. Novo Nordisk's next-generation experimental drug, CagriSema, delivered an estimated average weight loss of 12.4% in a late-stage trial in patients with diabetes,…...
Autobahn Therapeutics Reports AMPLIFY-BD Results for Elunetirom in Bipolar Depression, Highlighting Rapid, Robust, and Sustained Improvements in Depressive Symptoms and Functioning
4+ hour, 7+ min ago (118+ words) Elunetirom adjunctive treatment associated with rapid and robust improvements that deepened over 6-week treatment period Improvements in depressive symptoms accompanied by meaningful gains in functioning, including an 85% reduction from baseline in days lost to depression, tracking with clinician-reported measures Psych…...
Novo's CagriSema delivers superior weight loss versus tirzepatide in REIMAGINE 5 trial
11+ hour, 37+ min ago (414+ words) Published on 09/21/2026 at 06:25 am EDT Bagsværd, Denmark, 21 September 2026 – Novo Nordisk today announced topline results from the phase 3 REIMAGINE 5 and REDEFINE 9 trials of once-weekly CagriSema (cagrilintide and semaglutide), an investigational product, and Novo's next innovation in weight management and type 2 diabetes....
Gilberto Lopes: Daraxonrasib and the Value of Extending Survival in Metastatic Pancreatic Cancer - OncoDaily
13+ hour, 3+ min ago (94+ words) Gilberto Lopes, Professor and Chief of the Division of Medical Oncology at Sylvester Comprehensive Cancer Center, shared on X: Here is our preprint assessing the cost-effectiveness of daraxonrasib! Daraxonrasib nearly doubled median overall survival in previously treated metastatic pancreatic adenocarcinoma, in…...